Some retrospective studies and case reports have reported the poor efficacy of crizotinib treatment for ALK rearrangement NSCLC co-occurring with TP53, KRAS and EGFR mutations (20, 21). This evidence concerns the gene ALK and non-small cell lung carcinoma.